Clinical Trial Update: Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

A completed Phase 3 trial evaluating the efficacy and safety of CDP870 (certolizumab pegol) versus placebo in reducing signs and symptoms of rheumatoid arthriti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CDP870 (certolizumab pegol)

Snippet

Sponsor: UCB Pharma | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED